Search the Newsreel

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

RGX-202 BLA submission for Duchenne muscular dystrophy on track for Q3 2026 initiation, with potential accelerated approval in 2H 2027 Long-term surabgene lomparvovec (sura-vec, ABBV-RGX-314) data highlight durable safety and efficacy profile ahead of key catalyst Topline data from pivotal subretinal wet AMD studies, …

Earnings Flash (AVNT) Avient Corporation Reports Q2 Revenue $917.0M, vs. FactSet Est of $898.5M

Avient Corporation (AVNT) announced its second-quarter revenue reached $917.0 million, surpassing FactSet's estimate of $898.5 million. The company also posted Q2 adjusted EPS of $0.96 per share, exceeding FactSet's estimate of $0.89. Avient continues to maintain its quarterly dividend at $0.275 a share.

Avient Announces Second Quarter 2026 Results; Increases Full-Year Guidance

Second quarter sales grew 5.8% to $917 million, driven by 4.3% organic sales growth and 1.5% favorable foreign exchange, with organic growth in both business segments Second quarter GAAP EPS of $0.70 compared to $0.57 in the prior year quarter Second quarter adjusted EPS …

Avient reports Q2 sales $917M, adjusted EPS $0.96 and raises 2026 adjusted EPS guidance

Avient (AVNT) reported strong second-quarter 2026 results with $917 million in revenue and an adjusted diluted EPS of $0.96, a 20% increase year-over-year. The company also raised its full-year 2026 adjusted EPS guidance to $3.10–$3.25, citing organic sales growth, margin expansion, and strong cash …

Avient (NYSE: AVNT) lifts 2026 outlook after strong Q2 results

Avient (NYSE: AVNT) reported strong Q2 2026 results with sales up 5.8% to $917.0 million and adjusted EPS increasing 20% to $0.96, exceeding prior guidance. The company also saw adjusted EBITDA margins expand to a record 18.3% and repaid $50 million of debt. Consequently, …

Morgan Stanley Adjusts PT on BrightView Holdings to $12.50 From $14, Maintains Equalweight Rating

Morgan Stanley has lowered its price target for BrightView Holdings (BV) to $12.50 from $14, while keeping an Equalweight rating on the stock. This adjustment comes after BrightView Holdings reported its Q3 2026 earnings, posting an adjusted EPS of $0.17, which was below FactSet's …

Viemed Healthcare | 144: Notice of proposed sale of securities pursuant to Rule 144

This article announces a Form 144 filing by Viemed Healthcare, indicating a proposed sale of securities. The notice is made pursuant to Rule 144 of the Securities Act of 1933, which permits the public resale of restricted and controlled securities if certain conditions are …

First Trust Advisors LP Grows Stock Holdings in Avient Corporation $AVNT

BrightView Holdings, Inc. (NYSE:BV) Receives Average Recommendation of "Hold" from Analysts

BrightView Holdings, Inc. (NYSE:BV) has received an average "Hold" recommendation from analysts, with a consensus 12-month price target of $14.35. The company's fiscal Q3 revenue increased 1.3% year-over-year but missed estimates, and profitability significantly weakened with adjusted EBITDA and net income falling. Management provided …

First Trust Advisors LP Purchases 100,420 Shares of BrightView Holdings, Inc. $BV

First Trust Advisors LP increased its stake in BrightView Holdings, Inc. (NYSE:BV) by 42.7% in the first quarter, acquiring an additional 100,420 shares and bringing its total holdings to 335,460 shares valued at $3,955,000. Other institutional investors also adjusted their positions in BrightView. The …

FrontView REIT (FVR) Earnings Date and Reports 2026 $FVR

FrontView REIT (NYSE: FVR) back to profit and adds 27 properties

Avient sales grow 5.8% to $917M; $100M-$150M debt repayment expected

Latent View Analytics Limited (NSE:LATENTVIEW) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

FrontView REIT, Inc. (FVR) Q2 FFO Meet Estimates

AbbVie Inc. $ABBV Position Raised by GAMMA Investing LLC

GAMMA Investing LLC increased its holdings in AbbVie Inc. (ABBV) by 8.2% in the second quarter, bringing its total to 68,002 shares valued at $17.1 million. This increase reflects broader institutional confidence, with hedge funds and institutions collectively owning 70.23% of ABBV stock. The …

AbbVie Inc. Stock 12‑Month Price Target Raised to $275.44, Implies 13% Upside

AbbVie Inc.'s stock 12-month average price target has been increased to $275.44 by 25 analysts, up from $274.04. This new target suggests a potential 13% upside based on the Aug. 4 closing price. The consensus rating from 32 analysts remains "Buy," with 24 Buy …

Viemed Healthcare (VMD) Stock Price Sinks As Margin Pressure Clouds Growth

Viemed Healthcare's stock (VMD) dropped almost 16% despite increased Q2 2026 revenue, as net income and profit margins declined year-over-year. The market is reacting to margin pressure, with trailing net profit margin falling to 4.8% from 5.8%, raising questions about whether diversification efforts are …

Viemed Healthcare, Inc. $VMD Shares Bought by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership significantly increased its stake in Viemed Healthcare (NASDAQ:VMD) by 101.9% in the first quarter, now owning 1.85% of the company. Other institutional investors like Invesco and Martingale Asset Management also boosted their holdings. Despite beating revenue estimates, Viemed Healthcare missed …

BrightView Q3 Earnings Call Highlights

BrightView Holdings, Inc. 2026 Q3 - Results - Earnings Call Presentation (NYSE:BV) 2026-08-05

BrightView Holdings, Inc. (BV) has published its Q3 2026 earnings call presentation. The company reported an EPS of $0.17, missing estimates by $0.12, and revenue of $717.60 million, missing by $8.88 million, despite a 1.31% year-over-year increase. This article provides access to the slide …

AbbVie Plans to raise $8 billion to finance deal with Apogee Therapeutics

AbbVie Inc. plans to raise $8 billion through investment-grade bonds to fund its $10.9 billion acquisition of Apogee Therapeutics Inc. This strategic move aims to expand AbbVie's portfolio of anti-inflammatory drugs, particularly with Apogee's zumilokibart, a potential competitor to Sanofi's Dupixent. The acquisition reflects …

What AbbVie’s Q2 Earnings Reveal About the Cost of the Apogee Deal

AbbVie's Q2 2026 earnings beat Street estimates across the board, with revenue reaching $16.99 billion and adjusted EPS at $3.65. However, the positive performance was partially offset by a $0.14 dilution from the pending Apogee Therapeutics acquisition, which reduced the full-year guidance upgrade. Despite …

Earnings call transcript: BrightView misses Q3 2026 profit view, shares sink

Veolia Environnement: Information Relating to the Total Number of Voting Rights Forming the Share Capital

Article L. 238-8-II of the French commercial Code and article 223-16 of the AMF (French Financial Markets Authority) general regulation PARIS, August 05, 2026--(BUSINESS WIRE)--Regulatory News: Corporate name of the issuer: Veolia Environnement (Paris:VIE) 21 rue La Boétie 75008 PARIS FRANCE (ISIN code: FR0000124141-VIE) …

Is AbbVie’s (ABBV) BOTOX Masseter Bet Quietly Rewriting Its Post-Humira Growth Story?

Avient earnings on deck: Can materials firm sustain momentum?

Avient Corp. is set to release its second-quarter earnings, with analysts expecting strong performance following a first-quarter beat. Investors will focus on margin trends, demand patterns in key markets, and management's commentary on full-year guidance as the company navigates a shift towards sustainable chemicals. …

BrightView (NYSE:BV) Hits New 12-Month Low After Earnings Miss

BrightView Holdings Releases Q3 2026 Financial Results

BrightView Holdings (NYSE: BV) announced its Q3 2026 financial results, reporting adjusted earnings of $0.17 per share, significantly below the $0.29 consensus estimate. Despite the earnings miss, the company's revenue increased by 1.3% year-over-year to $717.6M, driven mainly by its Maintenance Services segment. BrightView …

Grupo Supervielle (SUPV) Projected to Release Earnings on Wednesday

Grupo Supervielle (SUPV) is expected to release its Q2 2026 earnings before market open on Wednesday, August 12th, with analysts forecasting earnings of $0.13 per share and revenue of $219.5840 million. The stock currently holds an average "Hold" rating from analysts with a consensus …

Here’s How Navient Corporation’s (NAVI) Leadership Is Setting Up a Re-Rating

Gator Capital Management, an investment management company, released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. In the Q2 2026 investor letter from Gator Capital Management, the firm reported strong absolute performance across its funds, demonstrating notable outperformance …

Prediction: AbbVie Will End The Year at This Price

24/7 Wall St. predicts AbbVie (ABBV) will end the year with a "buy" rating and a price target of $297.71, representing a 20.92% upside from its current price. This optimistic outlook is driven by the strong performance of drugs like Skyrizi and Rinvoq, which …

Is It Worth Investing in AbbVie (ABBV) Based on Wall Street's Bullish Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Let's …

Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout

Baron Capital, an investment management company, released its Q2 2026 investor letter for the "Baron Health Care Fund". A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 …

Central Pacific Bank Trust Division Sells 4,628 Shares of AbbVie Inc. $ABBV

Central Pacific Bank Trust Division significantly reduced its stake in AbbVie Inc. by 44.5% in the second quarter, selling 4,628 shares and retaining 5,766 shares valued at $1.45 million. Despite this sale, AbbVie reported strong second-quarter results with revenue up 10.2% and adjusted EPS …

Canandaigua National Bank & Trust Co. Acquires New Stake in AbbVie Inc. $ABBV

Canandaigua National Bank & Trust Co. has acquired a new stake in AbbVie Inc., purchasing 27,540 shares valued at approximately $6.93 million. This comes as AbbVie reported strong second-quarter results, exceeding analyst expectations with revenue up 10.2% year-over-year and solid EPS. The company also …